[HTML][HTML] Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report
W Peng, X Pu, M Jiang, J Wang, J Li, K Li, Y Xu, F Xu… - Lung Cancer, 2021 - Elsevier
Objective Dacomitinib is a potent, irreversible and pan-HER tyrosine kinase inhibitor (TKI) of
epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) …
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
J Zhang, Y Wang, Z Liu, L Wang, Y Yao, Y Liu… - Thoracic …, 2021 - Wiley Online Library
Background Dacomitinib is a second‐generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) which is superior to first‐generation EGFR TKI in ARCHER …
tyrosine kinase inhibitor (TKI) which is superior to first‐generation EGFR TKI in ARCHER …
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
KE Poels, AJ Schoenfeld, A Makhnin, Y Tobi… - Nature …, 2021 - nature.com
Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line
treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the …
treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the …
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic …
PM Ellis, N Coakley, R Feld, S Kuruvilla, YC Ung - Current oncology, 2015 - mdpi.com
Introduction: This systematic review addresses the use of epidermal growth factor receptor
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.
2509 Background: AZD9291 is an irreversible, mutant-selective EGFR tyrosine kinase
inhibitor (TKI) developed to have potency against EGFR mutations, including T790M, while …
inhibitor (TKI) developed to have potency against EGFR mutations, including T790M, while …
Dacomitinib: first global approval
M Shirley - Drugs, 2018 - Springer
Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li, Y Xu… - Bmc Cancer, 2023 - Springer
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience …
XL Mu, LY Li, XT Zhang, SL Wang, MZ Wang - BMC cancer, 2004 - Springer
Background The gefitinib compassionate-use programme has enabled> 39,000 patients
worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of …
worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of …
Recent advances of novel targeted therapy in non-small cell lung cancer
JA Katzel, MP Fanucchi, Z Li - Journal of hematology & oncology, 2009 - Springer
Lung cancer is the leading cause of cancer deaths world-wide. Recent advances in cancer
biology have led to the identification of new targets in neoplastic cells and the development …
biology have led to the identification of new targets in neoplastic cells and the development …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …